Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma

Nature Reviews Rheumatology

Volumn 7, Issue 6, 2011, Pages 360-368

  Dias, Catarina ^a   Isenberg, David A ^b  

^a HOSPITAL CENTRAL DO FUNCHAL   (Portugal)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXORUBICIN; EPRATUZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR; VELTUZUMAB; VINCRISTINE;

AGE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LYMPHOMA; B CELL NONHODGKIN LYMPHOMA; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENDER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

DISEASE SUSCEPTIBILITY; HUMANS; LYMPHOMA, B-CELL; RHEUMATIC DISEASES; RISK FACTORS;

EID: 79958113700     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.62     Document Type: Review

References (61)

1. Jaffe, E. S., Harris, N. L., Stein, H. & Isaacson, P. G. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 112, 4384-4399 (2008).
2. Grulich, A. E. & Vajdic, C. M. The epidemiology of non-Hodgkin lymphoma. Pathology 37, 409-419 (2005). (Pubitemid 43030867)
3. Goldin, L. R. & Landgren, O. Autoimmunity and lymphomagenesis. Int. J. Cancer 124, 1497-1502 (2009).
4. rd edn 1408-1420 (Saunders Elsevier, Philadelphia, 2007).
5. th edn 687-688 (McGraw-Hill Medical, New York, 2008).
6. Zintzaras, E., Voulgarelis, M. & Moutsopoulos, H. M. The risk of lymphoma development in autoimmune diseases: a meta- analysis. Arch. Intern. Med. 165, 2337-2344 (2005). (Pubitemid 41640845)
7. Alexander, D. D. et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int. J. Cancer 120 (Suppl.), 1-39 (2007). (Pubitemid 46732571)
8. Kiss, E., Kovacs, L. & Szodoray, P. Malignancies in systemic lupus erythematosus. Autoimmun. Rev. 9, 195-199 (2010).
9. Hansen, A., Lipsky, P. E. & Dörner, T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3, 561-569 (2007). (Pubitemid 47514471)
10. Baecklund, E. et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54, 692-701 (2006).
11. Smedby, K. E. et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J. Natl Cancer Inst. 98, 51-60 (2006). (Pubitemid 43057092)
12. Smedby, K. E. et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111, 4029-4038 (2008).
13. Mellemkjaer, L. et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum. 58, 657-666 (2008). (Pubitemid 351364863)
14. Anderson, L. A. et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int. J. Cancer 125, 398-405 (2009).
15. Ansell, P. et al. Non-Hodgkin lymphoma and autoimmunity: does gender matter? Int J Cancer. doi:10.1002/ijc.25680.
16. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
17. Smith, A. et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br. J. Haematol. 148, 739-753 (2010).
18. Kristinsson, S. Y. et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenström macroglobulinemia. J. Natl Cancer Inst. 102, 557-567 (2010).
19. Bernatsky, S. et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 52, 1481-1490 (2005). (Pubitemid 40663940)
20. Tincani, A., Taraborelli, M. & Cattaneo, R. Antiphospholipid antibodies and malignancies. Autoimmun. Rev. 9, 200-202 (2010).
21. Hellgren, K., Smedby, K. E., Feltelius, N., Baecklund, E. & Askling, J. Do rheumatoid arthritis and lymphoma share risk factors? A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum. 62, 1252-1258 (2010).
22. Lazarus, M. N., Robinson, D., Mak, V., Moller, H. & Isenberg, D. A. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology 45, 1012-1015 (2006). (Pubitemid 44283059)
23. Geborek, P. et al. Tumor necrosis factor do not increase overall risk in patient with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 64, 657-658 (2005).
24. De Vita, S. & Quartuccio, L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun. Rev. 5, 443-448 (2006). (Pubitemid 44233403)
25. Mariette, X. et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis. 69, 400-408 (2010).
26. Askling, J. et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol. Drug Saf. 20, 119-130 (2011).
27. Kovács, L., Szodoray, P. & Kiss, E. Secondary tumours in Sjögren's Syndrome. Autoimmun. Rev. 9, 203-206 (2010).
28. Bende, R. J., van Maldegem, F. & van Noesel, C. J. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica 94, 1109-1123 (2009).
29. Kristinsson, S. Y. et al. Genetic and immune- related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica 94, 1581-1589 (2009).
30. Goodnow, C. C. Multistep pathogenesis of autoimmune disease. Cell 130, 25-35 (2007). (Pubitemid 47031326)
31. Youinou, P. Is BAFF the murderer in lupus? Lupus 17, 613-614 (2008).
32. Tangye, S. G., Bryant, V. L., Cuss, A. K. & Good, K. L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18, 305-317 (2006). (Pubitemid 44287555)
33. Cellier, C. et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 356, 203-208 (2000). (Pubitemid 30446975)
34. Suarez, F., Lortholary, O., Hermine, O. & Lecuit, M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107, 3034-3044 (2006).
35. Bernatsky, S., Ramsey-Goldman, R. & Clarke, A. E. Malignancy in systemic lupus erythematosus: what have we learned? Best Pract. Res. Clin. Rheumatol. 23, 539-547 (2009).
36. Ramos-Casals, M. et al. Characterization of B cell lymphoma in patients with Sjogren's syndrome and hepatitis C virus infection. Arthritis Rheum 57, 161-170 (2007).
37. Brady, G., Macarthur, G. J. & Farrell, P. J. Epstein- Barr virus and Burkitt lymphoma. Postgrad. Med. J. 84, 372-377 (2008).
38. Calza, L. et al. Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. Int. J. STD AIDS 14, 356-359 (2003). (Pubitemid 36606115)
39. Reyes, S. L. I. et al. BAFF: a regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer [Spanish]. Rev. Med. Chil. 134, 1175-1184 (2006). (Pubitemid 44800177)
40. Wang, S. S. et al. Immune mechanisms in non- Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res. 67, 5042-5054 (2007). (Pubitemid 46910215)
41. Bayley, J. P., Ottenhoff, T. H. & Verweij, C. L. Is there a future for TNF promoter polymorphisms? Genes Immun. 5, 315-329 (2004). (Pubitemid 39139757)
42. Gibson, A. W. et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J. Immunol. 166, 3915-3922 (2001). (Pubitemid 32224918)
43. Balkwill, F. & Coussens, L. M. Cancer: an inflammatory link. Nature 431, 405-406 (2004). (Pubitemid 39329565)
44. Wang, S. S. et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 66, 9771-9780 (2006). (Pubitemid 44623679)
45. Chen, Y. et al. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index and risk of non-Hodgkin lymphoma. Blood 117, 585-589 (2011).
46. Toussirot, E. & Wendling, D. The use of TNF-α blocking agents in rheumatoid arthritis: an update. Expert Opin. Pharmacother. 8, 2089-2107 (2007). (Pubitemid 47505587)
47. Bernatsky, S. et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann. Rheum. Dis. 67, 74-79 (2008).
48. Dörner. T. & Lipsky, P. E. B-cell targeting: a novel approach to immune intervention today and tomorrow. Expert Opin. Biol. Ther. 7, 1287-1299 (2007). (Pubitemid 47475650)
49. Dörner, T. et al. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun. Rev. 9, 82-89 (2009).
50. Dörner, T., Kinnman, N. & Tak, P. P. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther. 125, 464-475 (2010).
51. Quartuccio, L. et al. Controversies on rituximab therapy in Sjögren syndrome-associated lymphoproliferation. Int. J. Rheumatol. 2009, 424935 (2009).
52. Edwards, J. C., Leandro, M. J. & Cambridge, G. Repeated B lymphocyte depletion therapy in rheumatoid arthritis: 5 year follow-up. Arthritis Rheum. 52 (Suppl.), S133-S134 (2005).
53. Popa, C., Leandro, M. J., Cambridge, G. & Edwards, J. C. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46, 626-630 (2007). (Pubitemid 46523308)
54. Watanabe, T. Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development. World J. Gastroenterol. 16, 5543-5554 (2010).
55. Voulgarelis, M., Giannouli, S., Tzioufas, A. G. & Moutsopoulos, H. M. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 65, 1033-1037 (2006). (Pubitemid 44133265)
56. Voulgarelis, M., Giannouli, S., Anagnostou, D. & Tzioufas, A. G. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone (CHOP) for Sjögren's syndrome- associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 43, 1050-1053 (2004). (Pubitemid 39144455)
57. Pijpe, J. et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740-2750 (2005). (Pubitemid 41369102)
58. Favas, C. & Isenberg, D. A. B-cell depletion therapy in SLE-what are the current prospects for its acceptance? Nat. Rev. Rheumatol. 5, 711-716 (2009).
59. Morschhauser, F. et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J. Clin. Oncol. 27, 3346-3353 (2009).
60. Milani, C. & Castillo, J. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr. Opin. Mol. Ther. 11, 200-207 (2009).
61. Steinfeld, S. D. et al. Epratuzumab (humanized anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Ar thritis Res. Ther. 8, R129 (2006).